Decitabine, Cedazuridine, and Venetoclax Approved for Older and High-Risk Adults

FDA Approves Oral Combination Therapy for Newly Diagnosed Acute Myeloid Leukemia

In a significant development for oncology, the Food and Drug Administration (FDA) has approved an oral combination of decitabine and cedazuridine tablets, used in conjunction with venetoclax, for the treatment of newly diagnosed acute myeloid leukemia (AML). This approval provides a new therapeutic pathway for patients who may not be candidates for traditional, intensive induction chemotherapy.

The approved regimen is specifically indicated for adults aged 75 years or older, as well as those with comorbidities that preclude the use of intensive induction chemotherapy. The combination includes Inqovi (manufactured by Taiho Oncology, Inc.) alongside venetoclax, offering a non-intravenous option for this vulnerable patient population.

Clinical Efficacy and Study Results

The FDA’s decision was supported by data from the ASTX727-07 clinical trial (NCT04657081). This study was a single-arm, open-label clinical trial involving 101 adults with newly diagnosed AML who met the specified age or comorbidity criteria.

The primary measures of efficacy for this treatment were complete remission (CR) and the duration of complete remission (DoCR). The clinical findings revealed the following:

• Complete Remission Rate: 42 patients achieved a CR, representing 41.6% of the study group (95% CI: 31.9, 51.8).
• Median Time to CR: Patients reached complete remission in a median of two months (with a range of 0.4 to 15.3 months).
• Duration of Remission: The median duration of CR was not reached during the study, with a recorded range of 0.5 to 16.3 months.

Dosage and Administration

The treatment is designed as an oral regimen to improve patient management. According to the FDA, the recommended dosage for Inqovi in combination with venetoclax is as follows:

Patients should take one Inqovi tablet—which contains 35 mg of decitabine and 100 mg of cedazuridine—orally once daily. This administration occurs on Days 1 through 5 of each 28-day cycle. Treatment continues until disease progression or until unacceptable toxicity occurs.

Regulatory Context: Project Orbis

This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. This framework allows for the concurrent submission and review of oncology drugs among international partners. During this specific review process, the FDA collaborated with Health Canada.

Safety Considerations and Precautions

While this oral combination offers a vital alternative to intensive chemotherapy, the prescribing information includes critical warnings. Healthcare providers must monitor patients closely for:

• Myelosuppression: A reduction in bone marrow activity that can lead to decreased blood cell production.
• Embryo-fetal toxicity: Potential risks to a developing fetus, requiring appropriate counseling and precautions.

Key Takeaways

As oncology moves toward more personalized and less invasive delivery methods, the approval of all-oral regimens like this one represents a significant step forward in improving the quality of life and treatment accessibility for elderly and high-risk AML patients.